MA29836B1 - Proteines de fusion avec l'albumine - Google Patents

Proteines de fusion avec l'albumine

Info

Publication number
MA29836B1
MA29836B1 MA30727A MA30727A MA29836B1 MA 29836 B1 MA29836 B1 MA 29836B1 MA 30727 A MA30727 A MA 30727A MA 30727 A MA30727 A MA 30727A MA 29836 B1 MA29836 B1 MA 29836B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
albumin fusion
albumin
vectors
host cells
Prior art date
Application number
MA30727A
Other languages
English (en)
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
Craig Rosen
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MA29836B1 publication Critical patent/MA29836B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention englobe des protéines de fusion d'albumine. Les molécules d'acides nucléiques codant pour les protéines de fusion d'albumine de l'invention sont également englobées par l'invention, de même que les vecteurs contenant ces acides nucléiques, les cellules hôtes transformées avec ces vecteurs d'acides nucléiques, et les procédés de fabrication des protéines de fusion d'albumine de l'invention et utilisant ces acides nucléiques, vecteurs, et/ou cellules hôtes. De plus, la présente invention comprend des compositions pharmaceutiques comprenant les protéines de fusion d'albumine et les procédés de traitement, de prévention, ou d'amélioration de maladies, troubles pathologies utilisant les protéines de fusion d'albumine de l'invention.
MA30727A 2005-08-12 2008-03-07 Proteines de fusion avec l'albumine MA29836B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
MA29836B1 true MA29836B1 (fr) 2008-10-03

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30727A MA29836B1 (fr) 2005-08-12 2008-03-07 Proteines de fusion avec l'albumine

Country Status (13)

Country Link
EP (1) EP1924596A4 (fr)
JP (1) JP2009504157A (fr)
KR (1) KR20080071119A (fr)
AU (1) AU2006280312A1 (fr)
BR (1) BRPI0614761A2 (fr)
CA (1) CA2618476A1 (fr)
EC (1) ECSP088262A (fr)
IL (1) IL189246A0 (fr)
MA (1) MA29836B1 (fr)
MX (1) MX2008001865A (fr)
NO (1) NO20081233L (fr)
TN (1) TNSN08064A1 (fr)
WO (1) WO2007021494A2 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1274720A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines fusionnees a l'albumine
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2663352A1 (fr) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Proteines de fusion d'albumine
EP2423219B1 (fr) 2007-01-30 2015-04-29 Epivax, Inc. Épitopes de lymphocytes T régulateurs, compositions et utilisations de ceux-ci
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
MX2011007583A (es) * 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
WO2010092135A2 (fr) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Variants de l'albumine et leurs conjugués
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
CN102741280B (zh) * 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
ES2674567T3 (es) * 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
WO2012118042A1 (fr) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Agent médicinal pour l'inhibition de la métastase d'une tumeur maline
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2838833A1 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composes pro-coagulants et leurs procedes d'utilisation
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (fr) 2011-10-21 2015-05-05 Abbvie Inc. Methodes de traitement du vhc
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP2804623B1 (fr) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Facteur viii chimérique et polypeptides et leurs utilisations
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
EP2863940A4 (fr) 2012-06-08 2016-08-10 Biogen Ma Inc Facteurs de coagulation chimériques
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014072481A1 (fr) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Variants d'albumine
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
WO2014125082A1 (fr) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Modèle pharmacocinétique animal
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3048899B1 (fr) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
WO2016004113A1 (fr) 2014-06-30 2016-01-07 Biogen Ma Inc. Gène du facteur ix optimisé
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
WO2017029407A1 (fr) 2015-08-20 2017-02-23 Albumedix A/S Variants de l'albumine et leurs conjugués
CA3000742A1 (fr) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Proteines therapeutiques bispecifiques pour la reparation de tissus
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018112362A1 (fr) 2016-12-16 2018-06-21 Biogen Ma Inc. Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
WO2018144623A1 (fr) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
MA50141A (fr) * 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
BR112021010047A2 (pt) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Uso de vetores lentivirais expressando o fator ix
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
WO2022030580A1 (fr) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Nouveau dérivé d'adrénomédulline à action prolongée, son procédé de production, et son utilisation pharmaceutique
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2513213C (fr) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
JP5010923B2 (ja) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
NO20081233L (no) 2008-05-09
EP1924596A2 (fr) 2008-05-28
ECSP088262A (es) 2008-05-30
AU2006280312A1 (en) 2007-02-22
WO2007021494A3 (fr) 2007-07-26
TNSN08064A1 (en) 2009-07-14
KR20080071119A (ko) 2008-08-01
MX2008001865A (es) 2008-04-15
BRPI0614761A2 (pt) 2009-05-19
CA2618476A1 (fr) 2007-02-22
EP1924596A4 (fr) 2009-07-29
WO2007021494A2 (fr) 2007-02-22
IL189246A0 (en) 2008-08-07
JP2009504157A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MA30340B1 (fr) Nouveaux composes
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE602005021072D1 (de) Adzyme und deren verwendungen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA30337B1 (fr) Anticorps
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EA200802054A1 (ru) Ингибиторы фермента
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
NO20054957L (no) Subtituerte karboksylsyrer
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
WO2008127680A3 (fr) Diagnostic et traitement de maladies causées par des protéines mal pliées
MA34225B1 (fr) Préparation stable de mia/cd-rap
EP1178796A4 (fr) Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie